Mesoblast Limited

Channel 10 News - 3 June 2005

Transcript

NEWSREADER :

World first research could slash recovery time for some broken bones and other medical conditions. And the Melbourne-based scientists say the technology may even revolutionise injury treatment for elite athletes.

REPORTER :

A horrific injury that could end a lucrative and blossoming career. Both bones in Nathan Brown's legs snapped, meaning he'll be out of footy indefinitely. Researchers say new stem cell technology could reduce recovery time for some fractures by as much as 50 per cent, even suggesting players bank stem cells as a biological insurance policy.

PROFESSOR SILVIU ITESCU, MESOBLAST :

If this athlete had a very severe, traumatic injury that potentially could be career threatening, you'd have these cells ready and available to be inserted directly into that fracture site.

REPORTER :

Brown's fracture is healing well of its own accord, but Professor Itescu says it's precisely the type of injury that could benefit.

ITESCU :

We then can have a million-fold increase in these type of cells and accelerate and repair the bone fracture.

REPORTER :

But applications for the research extend far beyond broken bones and elite athletes. Regeneration of soft tissues and even heart muscles will feature in the first clinical trials over the next few weeks.

DR RODNEY DILLEY – RESEARCH SCIENTIST :

People with intervertebral disc injuries can get repaired. People with arthritis and severe articular cartilage damage can get repaired.

REPORTER :

As well as the medical benefits, the research could open the door to a largely untapped, multi-billion dollar market.

 

END OF SEGMENT

 

 

For further information, please call:

Julie Meldrum
Mesoblast Limited
0419 228 128
julie.meldrum@mesoblast.com

>>back to What They Say

 

 

Last Share Price

14 February 2011 – Mesoblast Issues New Equity to Cephalon, Receives Further Cash Injection

9 February 2011 – Chairman’s Address, CEO Presentation to EGM

31 January 2011 – Mesoblast Reports Strong Cash Position; Appendix 4C Quarterly Cash Flow Report

12 January 2011 Mesoblast – Cephalon Alliance Highlighted at JP Morgan Healthcare Conference

10 January 2011 - Interim Results from Mesoblast’s Phase 2 Heart Failure Trial Shows “Off-the-Shelf” Proprietary Adult Stem Cell Product Revascor Reduces Cardiac Events, Mortality, and Hospitalization

23 December 2010 – Mesoblast Completes Acquisition of Angioblast

8 December 2010 – Mesoblast and Cephalon Enter into Strategic Alliance to Commercialize Novel Therapeutic Products for Regenerative Medicine

29 November 2010 – Building a solid futurec

19 November 2010 – Mesoblast Clear to Proceed with Angioblast Acquisition

16 November 2010 – Positive Results of Novel Heart Attack Treatment Presented at Premier USA Cardiology Conference

8 November 2010 - U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products

29 October 2010 - Notice of AGM

29 October 2010 - Mesoblast Annual Report 2010

21 October 2010 – Positive Results from Phase 2 Lumbar Fusion Trial Presented at International Investor Conference

20 October 2010 - Mesoblast Acquisition of US Company Approved by Angioblast Stockholders

14 October 2010 – Mesoblast targets broader cancer indications for bone marrow transplant product

23 September 2010 – Boardroom radio interview with CEO Silviu Itescu

22 September 2010 - Acquisition of US Company Ratified by Mesoblast Shareholders

22 September 2010: Results of Extraordinary General Meeting

22 September 2010 – Chairman Speech & CEO Presentation to EGM

20 September 2010 – Mesoblast Featured at International Scientific Conferences

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

30 November 2010 - Nomura Research; Mining the Marrow

22 November 2010 - Nomura Research: Mesoblast [MSB AU] - BUY: Trial Results Continue to Impress

16 November 2010 - Nomura Research: Mesoblast Buy: Releases Positive Clinical Trial Data in Heart Disease; NPV $19

8 October 2010 – Nomura Research: Updating forecasts for Angioblast

10 September 2010 - Southern Cross Equities Note to Clients : Mesoblast No. 1 Biotech Recommendation

10 September 2010 - Bioshares Analysis: Mesoblast Continues to Open New Product Opportunities

26 August 2010 - Nomura Global Equities Research: FY 2010 Making Their Bones

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

6 July 2010 - Nomura Global Equities Research: A Biotech Platform Technology; Anchor Report

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine